Endocrine System Diseases  >>  pioglitazone  >>  Phase 2
Welcome,         Profile    Billing    Logout  

21 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pioglitazone / Generic mfg.
NCT00760578: A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

Completed
2a
86
US
Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
Metabolic Solutions Development Company
Type 2 Diabetes Mellitus
01/09
02/09
NCT01280695: A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Completed
2a
129
US
Placebo, MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
Metabolic Solutions Development Company
Diabetes Mellitus, Type 2
06/11
06/11
NCT00676260: Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin

Completed
2
29
Europe
Pioglitazone, Actos, AD4833, Placebo
Takeda
Diabetes Mellitus
08/04
08/04
NCT00762736: Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

Completed
2
704
US, RoW
Pioglitazone and azilsartan, ACTOS®, AD4833, TAK-536, Pioglitazone
Takeda
Diabetes Mellitus
10/05
10/05
NCT00229684: ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

Terminated
2
100
US
Tesaglitazar, Galida, pioglitazone, Actos
AstraZeneca
Diabetes Mellitus, Type 2
06/06
06/06
NCT00196989 / 2006-001275-38: Study In People With Type 2 Diabetes

Completed
2
448
US, Canada, Europe, RoW
Pioglitazone, GW677954
GlaxoSmithKline
Diabetes Mellitus, Type 2
04/07
04/07
NCT00543959: Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

Terminated
2
346
US
MK0533, Comparator: Placebo (unspecified), Comparator: pioglitazone
Merck Sharp & Dohme LLC
Diabetes Mellitus Type 2
08/07
08/07
NCT00461058: A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

Completed
2
14
US, Europe, RoW
Actos, aleglitazar
Hoffmann-La Roche
Diabetes Mellitus Type 2
12/07
12/07
NCT00500331 / 2006-004694-97: Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

Completed
2
334
US, Europe, RoW
GSK189075, pioglitazone, Placebo
GlaxoSmithKline
Diabetes Mellitus, Type 2
02/08
02/08
NCT00388518: A Study of Aleglitazar in Patients With Type 2 Diabetes

Checkmark P2 data
Sep 2012 - Sep 2012: P2 data
Checkmark P2 data
Mar 2012 - Mar 2012: P2 data
Completed
2
332
US, Europe, RoW
Actos, Placebo, aleglitazar
Hoffmann-La Roche
Diabetes Mellitus Type 2
03/08
03/08
RAISE, NCT00575874: Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes

Completed
2
150
RoW
Rivoglitazone HCl, rivoglitazone HCl, pioglitazone HCl, placebo
Daiichi Sankyo Co., Ltd.
Type 2 Diabetes
06/08
01/09
NCT00461006: A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Completed
2
176
US, RoW
Actos, aleglitazar
Hoffmann-La Roche
Diabetes Mellitus Type 2
09/08
09/08
NCT00722917: Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Terminated
2
323
US
TAK-379, Actos, Pioglitazone, AD4833, Placebo
Takeda
Diabetes Mellitus
04/09
04/09
NCT00631007: A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

Completed
2
367
US, RoW
INT131 besylate, Pioglitazone HCl, Actos, Placebo
InteKrin Therapeutics, Inc.
Type 2 Diabetes Mellitus
08/09
09/09
PIOren, NCT00770640 / 2007-006744-21: Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.

Completed
2
40
Europe
Pioglitazone and insulin, ACTOS®, AD-4833, Insulin
Takeda
Diabetes Mellitus
06/10
06/10
NCT01028963 / 2009-016051-22: A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

Checkmark POC data in diabetic nephropathy
May 2013 - May 2013: POC data in diabetic nephropathy
Checkmark Data
Jul 2011 - Jul 2011: Data
Checkmark Data
More
Completed
2
159
Europe, RoW
Placebo, pioglitazone, CCX140-B
ChemoCentryx
Type 2 Diabetes Mellitus
10/10
11/10
NCT01230749: A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus

Completed
2
89
US
JNJ-41443532, Pioglitazone 30 mg, Placebo
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
06/11
06/11
GCPD, NCT01346254: Glucose Control in Pre-Diabetic Renal Transplant Patients

Checkmark
Feb 2013 - Feb 2013: 
Checkmark
Feb 2013 - Feb 2013: 
Completed
2
51
Europe
Vildagliptin, Galvus, Pioglitazone, Actos, Life-Style Modification
Marcus Saemann
Impaired Glucose Tolerance, Kidney Transplantation
11/11
11/11
NCT01043029 / 2009-012270-12: A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Checkmark ADA 2013
Jun 2013 - Jun 2013: ADA 2013
Checkmark Effect on cardiovascular risk factor
Mar 2013 - Mar 2013: Effect on cardiovascular risk factor
Completed
2
302
Europe, RoW
aleglitazar, pioglitazone
Hoffmann-La Roche
Diabetes Mellitus Type 2
07/12
07/12
NCT01655719: Pioglitazone in Thyroid Cancers

Completed
2
1
US
Pioglitazone, Actos
University of Michigan, National Cancer Institute (NCI)
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
03/17
03/17
NCT01396564: Pioglitazone and Metformin in Diabetic Children

Completed
1/2
56
RoW
Metformin, Recommended diet and 30 minutes of exercise daily, Pioglitazone
Coordinación de Investigación en Salud, Mexico
Type 2 Diabetes
10/06
07/11

Download Options